Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.83 USD | -2.83% | -5.66% | +15.45% |
05-15 | Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target | MT |
05-09 | Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.45% | 735M | |
+18.80% | 125B | |
+14.18% | 108B | |
-4.72% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.51% | 13.39B | |
+27.83% | 11.1B |
- Stock Market
- Equities
- WVE Stock
- News Wave Life Sciences Ltd.
- Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q2 Revenue $22.1M, vs. Street Est of $7.9M